Lynn Seely, CEO of Myovant Sciences, said: “We are now closer to our goal of bringing a precision oral medicine to the broad spectrum of men with advanced prostate cancer.” Shares of Myovant Sciences …
More Myovant: Relugolix Phase 3 Study Meets Endpoints In Advanced Prostate Cancer Videos